What is MiRXES?
Founded in 2014, MiRXES has established itself as a leader in microRNA biomarker profiling, leveraging its world-class technology to address critical challenges in the medical, pharmaceutical, agricultural, and veterinary sectors. By bridging the gap between innovative laboratory science and commercial application, the company develops accessible and accurate diagnostic solutions. Its operational model focuses on building a comprehensive ecosystem that integrates clinicians, researchers, and corporate partners to accelerate the transition of scientific breakthroughs into real-world clinical outcomes, effectively positioning the firm at the forefront of precision medicine.
How much funding has MiRXES raised?
MiRXES has raised a total of $167M across 3 funding rounds:
Series C
$77M
Series D
$50M
Debt
$40M
Series C (2021): $77M with participation from CR-CP Life Science Fund, EDBI, and Rock Springs Capital
Series D (2023): $50M led by Fupu Investment Management, NHH Venture Fund, and MITSUI & CO LTD
Debt (2025): $40M supported by CBC Group
Key Investors in MiRXES
CBC Group
CBC Group is a premier healthcare-dedicated investment firm in Asia, specializing in platform-building and buyout opportunities across the pharmaceutical, biotech, and medtech sectors.
MITSUI & CO LTD
Mitsui & Co. is a diversified global investment firm that leverages its extensive cross-industry network to deliver long-term value, with a specific strategic focus on enhancing healthcare solutions and quality of life.
EDBI
EDBI is a Singapore-based global investor that supports high-growth technology companies, providing strategic capital to foster innovation and industrial development.
What's next for MiRXES?
With this latest infusion of capital, MiRXES is well-positioned to accelerate its strategic roadmap, which includes the expansion of its global footprint and the further commercialization of its microRNA-based diagnostic pipeline. The company is expected to leverage these resources to deepen its R&D efforts, focusing on the eradication of disease through early detection and improved patient outcomes. As the firm continues to scale, the focus will likely shift toward strengthening its international network and optimizing its manufacturing labs to meet the growing demand for high-precision, affordable healthcare solutions on a global scale.
See full MiRXES company page
